Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1043-1048

  Arana Yi, Cecilia ^a   Block, AnneMarie W ^a   Sait, Sheila N ^a   Ford, Laurie A ^a   Barcos, Maurice ^a   Baer, Maria R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Cytarabine; Myelodysplastic syndrome; Therapy related

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; MELPHALAN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME 7; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; CYTARABINE; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 41949088701     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.006     Document Type: Article

References (36)

1. Park D.J., and Koeffler H.P. Therapy related myelodysplastic syndromes. Semin Hematol 33 (1996) 256-273
2. Smith S.M., Le Beau M.M., Huo D., Karrison T., Sobecks R.M., Anastasi J., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia; the University of Chicago series. Blood 102 (2003) 43-52
3. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France
4. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., and Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99 (2002) 1909-1912
5. LeBeau M., Albain K.S., Larson R.A., Vardiman J.W., Davis E.M., Blough R.R., et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no 5 and 7. J Clin Oncol 4 (1986) 325-345
6. Bloomfield C.D., Archer K.J., Mrózek K., Lillington D.M., Kaneko Y., Head D.R., et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 33 (2002) 362-378
7. Pui C.H., Ribeiro R.C., Hancock M.L., Rivera G.K., Evans W.E., Raimondi S.C., et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325 (1991) 1682-1687
8. Winick N.J., McKenna R.W., Shuster J.J., Schneider N.R., Borowitz M.J., Bowman W.P., et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11 (1993) 209-217
9. Relling M.V., Boyett J.M., Blanco J.G., Raimondi S., Behm F.G., Sandlund J.T., et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101 (2003) 3862-3867
10. Garcia-Manero G., Kantarjian H.M., Kornblau S., and Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia. Leukemia 16 (2002) 1888
11. Latagliata R., Petti M.C., Fenu S., Mancini M., Spiriti M.A., Breccia M., et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 99 (2002) 822-824
12. Pawarode A., Finlay E., Barcos M., Sait S.N.J., and Baer M.R. Isochromosome 1q in a myelodysplastic syndrome following treatment of acute promyelocytic leukemia. Cancer Genet Cytogenet 167 (2006) 155-160
13. Hamamoto K., Hashimoto-Ninomiya A., Kishimoto Y., Kimura T., Fujitake H., and Yasunaga K. Unbalanced 1;7 translocation in myelodysplastic syndrome following treatment of acute myeloblastic leukemia with 8;21 translocation. Cancer Genet Cytogenet 74 (1994) 35-39
14. Roulston D., Anastasi J., Rudinsky R., Nucifora G., Zeleznik-Le N., Rowley J.D., et al. Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia: a report of two cases. Blood 86 (1995) 3613-3614
15. Seiter K., Feldman E.J., Sreekantaiah C., Pozzuoli M., Weisberger J., Liu D., et al. Secondary acute myeloid leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 15 (2001) 963-970
16. Sakai C., Matsubayashi M., Saotome T., Ishii A., and Kumagai K. Therapy-related myelodysplastic syndrome with trisomy 1q due to der(1;7) and megakaryoblastic proliferation during complete remission of therapy-related acute myeloid leukemia with t(8;21). Intern Med 43 (2004) 582-586
17. Ogasawara T., Yasuyama M., and Kawauchi K. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia. Am J Hematol 79 (2005) 136-141
18. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 (1985) 620-625
19. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
20. Baer M.R., Stewart C.C., Dodge R.K., Leget G., Sule N., Mrozek K., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B study 8361). Blood 97 (2001) 3574-3580
21. ISCN (2005) An international system for human cytogenetic nomenclature, In: Mitelman F editor. Basel, Switzerland, Karger; 2005.
22. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21 (2003) 4642-4649
23. Mecucci C., Van Orshoven A., Boogaerts M., Michaux J.L., and Van den Berghe H. Characterization of deletions of chromosome 7 short arm occurring as primary karyotypic anomaly in acute myeloid leukaemia. Br J Haematol 71 (1989) 13-17
24. Mitelman F, Johansson B, Mertens F. In: Mitelman editor. Database of chromosome aberrations in cancer; 2007, http://cgap.nci.nih.gov/Chromosomes/Mitelman.
25. Pedersen-Bjergaard J., Andersen M.K., and Christiansen D.H. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95 (2000) 3273-3279
26. Freedman M.H., Bonilla M.A., Fier C., Bolyard A.A., Scarlata D., Boxer L.A., et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 96 (2000) 429-436
27. Sloand E.M., Yong A.S., Ramkissoon S., Solomou E., Bruno T.C., Kim S., et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA 103 (2006) 14483-14488
28. Kwong Y.L., Au W.Y., and Liang R.H. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with-7/7q-. Cancer Genet Cytogenet 104 (1998) 94-97
29. Knipp S., Hildebrandt B., Richter J., Haas R., Germing U., and Gattermann N. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 90 (2005) 691-693
30. Heizer W.D., and Peterson J.L. Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine. Dig Dis Sci 43 (1998) 1791-1793
31. Lam C.C., Ma E.S., and Kwong Y.L. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia. Am J Hematol 79 (2005) 288-290
32. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 98 (2001) 11592-11597
33. Seedhouse C., Bainton R., Lewis M., Harding A., Russell N., and Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 100 (2002) 3761-3766
34. Seedhouse C., Faulkner R., Ashraf N., Das-Gupta E., and Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 10 (2004) 2675-2680
35. Jawad M., Seedhouse C.H., Russell N., and Plumb M. Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood 108 (2006) 3916-3918
36. Smith A.G., Worrillow L.J., and Allan J.M. A common genetic variant in XPD associates with risk of 5q and 7q deleted acute myeloid leukemia. Blood 109 (2007) 1233-1236